Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

Endothelial ERK1/2 signaling maintains integrity of the quiescent endothelium.

Ricard N, Scott RP, Booth CJ, Velazquez H, Cilfone NA, Baylon JL, Gulcher JR, Quaggin SE, Chittenden TW, Simons M.

J Exp Med. 2019 Aug 5;216(8):1874-1890. doi: 10.1084/jem.20182151. Epub 2019 Jun 13.

PMID:
31196980
2.

Enhancing Retrosynthetic Reaction Prediction with Deep Learning Using Multiscale Reaction Classification.

Baylon JL, Cilfone NA, Gulcher JR, Chittenden TW.

J Chem Inf Model. 2019 Feb 25;59(2):673-688. doi: 10.1021/acs.jcim.8b00801. Epub 2019 Feb 1.

PMID:
30642173
3.

M281, an Anti-FcRn Antibody: Pharmacodynamics, Pharmacokinetics, and Safety Across the Full Range of IgG Reduction in a First-in-Human Study.

Ling LE, Hillson JL, Tiessen RG, Bosje T, van Iersel MP, Nix DJ, Markowitz L, Cilfone NA, Duffner J, Streisand JB, Manning AM, Arroyo S.

Clin Pharmacol Ther. 2019 Apr;105(4):1031-1039. doi: 10.1002/cpt.1276. Epub 2018 Dec 4.

4.

Dynamic balance of pro- and anti-inflammatory signals controls disease and limits pathology.

Cicchese JM, Evans S, Hult C, Joslyn LR, Wessler T, Millar JA, Marino S, Cilfone NA, Mattila JT, Linderman JJ, Kirschner DE.

Immunol Rev. 2018 Sep;285(1):147-167. doi: 10.1111/imr.12671. Review.

5.

Th17 cytokines differentiate obesity from obesity-associated type 2 diabetes and promote TNFα production.

Ip B, Cilfone NA, Belkina AC, DeFuria J, Jagannathan-Bogdan M, Zhu M, Kuchibhatla R, McDonnell ME, Xiao Q, Kepler TB, Apovian CM, Lauffenburger DA, Nikolajczyk BS.

Obesity (Silver Spring). 2016 Jan;24(1):102-12. doi: 10.1002/oby.21243. Epub 2015 Nov 18.

6.

Quantitative Systems Pharmacology Approaches Applied to Microphysiological Systems (MPS): Data Interpretation and Multi-MPS Integration.

Yu J, Cilfone NA, Large EM, Sarkar U, Wishnok JS, Tannenbaum SR, Hughes DJ, Lauffenburger DA, Griffith LG, Stokes CL, Cirit M.

CPT Pharmacometrics Syst Pharmacol. 2015 Oct;4(10):585-94. doi: 10.1002/psp4.12010. Epub 2015 Oct 5.

7.
8.

Systems Pharmacology Approach Toward the Design of Inhaled Formulations of Rifampicin and Isoniazid for Treatment of Tuberculosis.

Cilfone NA, Pienaar E, Thurber GM, Kirschner DE, Linderman JJ.

CPT Pharmacometrics Syst Pharmacol. 2015 Mar;4(3):e00022. doi: 10.1002/psp4.22. Epub 2015 Mar 11.

9.

A multi-scale approach to designing therapeutics for tuberculosis.

Linderman JJ, Cilfone NA, Pienaar E, Gong C, Kirschner DE.

Integr Biol (Camb). 2015 May;7(5):591-609. doi: 10.1039/c4ib00295d. Epub 2015 Apr 30.

10.

Computational modeling predicts IL-10 control of lesion sterilization by balancing early host immunity-mediated antimicrobial responses with caseation during mycobacterium tuberculosis infection.

Cilfone NA, Ford CB, Marino S, Mattila JT, Gideon HP, Flynn JL, Kirschner DE, Linderman JJ.

J Immunol. 2015 Jan 15;194(2):664-77. doi: 10.4049/jimmunol.1400734. Epub 2014 Dec 15.

11.

A computational tool integrating host immunity with antibiotic dynamics to study tuberculosis treatment.

Pienaar E, Cilfone NA, Lin PL, Dartois V, Mattila JT, Butler JR, Flynn JL, Kirschner DE, Linderman JJ.

J Theor Biol. 2015 Feb 21;367:166-179. doi: 10.1016/j.jtbi.2014.11.021. Epub 2014 Dec 9.

12.

Macrophage polarization drives granuloma outcome during Mycobacterium tuberculosis infection.

Marino S, Cilfone NA, Mattila JT, Linderman JJ, Flynn JL, Kirschner DE.

Infect Immun. 2015 Jan;83(1):324-38. doi: 10.1128/IAI.02494-14. Epub 2014 Nov 3.

13.

Multi-scale modeling predicts a balance of tumor necrosis factor-α and interleukin-10 controls the granuloma environment during Mycobacterium tuberculosis infection.

Cilfone NA, Perry CR, Kirschner DE, Linderman JJ.

PLoS One. 2013 Jul 15;8(7):e68680. doi: 10.1371/journal.pone.0068680. Print 2013.

Supplemental Content

Loading ...
Support Center